

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE

Health Technology Appraisal

Bevacizumab and cetuximab for the treatment of advanced colorectal cancer

Response to consultee and commentator comments on the provisional matrix of consultees and commentators

	Proposed consultee:	Proposal made by:	Action taken:	Justification:
1.	NCRI should be consultees and not commentators	Roche	<input type="checkbox"/> No action	NCRI is a research group not a manufacturer, patient or professional group, and therefore qualifies as a commentator and not consultee.
2.	NCRN Colorectal Cancer Subgroup should be commentators	Roche	<input type="checkbox"/> Added	The National Cancer Research Network has been added as a commentator as requested.